Table 3.
Clinical Outcomes and Analysis by Carboplatin Dose
| Variable | No. | % | 95% CI | No. | % | 95% CI |
|---|---|---|---|---|---|---|
| Median PFS, months (n = 47) | 6.5 | 4.7 to 7.8 | ||||
| Median OS, months (n = 47) | 13.9 | 11.9 to 18.1 | ||||
| Response outcomes (n = 47) | ||||||
| CR and PR | 23 | 49 | ||||
| SD | 11 | 23 | ||||
| AUC 5.0(n = 11) | AUC 4.5(n = 36) | |||||
|---|---|---|---|---|---|---|
| Analysis by initial carboplatin AUC dose | ||||||
| Age, years | ||||||
| Median | 67 | 68 | ||||
| Range | 53-82 | 42-83 | ||||
| Sex | ||||||
| Male | 8 | 73 | 28 | 78 | ||
| Female | 3 | 27 | 8 | 22 | ||
| KPS | ||||||
| 70 | 1 | 9 | 5 | 14 | ||
| 80 | 8 | 73 | 14 | 39 | ||
| 90 | 2 | 18 | 17 | 47 | ||
| MSKCC risk group | ||||||
| 0 | 3 | 27 | 9 | 25 | ||
| 1 | 8 | 73 | 23 | 64 | ||
| 2 | 0 | 0 | 4 | 11 | ||
| Median PFS, months | 11.9 | 5.7 to N/A | 6.3 | 4.6 to 7.2 | ||
| Response outcomes | ||||||
| CR and PR | 7 | 64 | 16 | 44 | ||
| SD | 2 | 18 | 9 | 25 | ||
Abbreviations: AUC, area under the [concentration-time] curve; CR, complete response; KPS, Karnofsky performance status; MSKCC, Memorial Sloan-Kettering Cancer Center; PFS, progression-free survival; PR, partial response; N/A, not assessable; OS, overall survival; SD, stable disease.